{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:24:10Z","timestamp":1791357850480,"version":"4.3.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shandong Provincial Natural Science Fund Committee","award":["ZR2021MH394"],"award-info":[{"award-number":["ZR2021MH394"]}]},{"name":"Shandong Provincial Health and Wellness Committee","award":["M-2022265"],"award-info":[{"award-number":["M-2022265"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-024-04146-x","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T20:19:20Z","timestamp":1720556360000},"page":"3559-3568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Renal anemia: from relative insufficiency of EPO to imbalance of erythropoiesis and eryptosis"],"prefix":"10.1007","volume":"56","author":[{"given":"Mengxue","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruilin","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiling","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhentao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"issue":"7","key":"4146_CR1","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2017","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, Hobbs FDR (2017) Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis. J PLoS ONE 11(7):e0158765","journal-title":"J PLoS ONE"},{"issue":"24","key":"4146_CR2","doi-asserted-by":"publisher","first-page":"e3872","DOI":"10.1097\/md.0000000000003872","volume":"95","author":"Y Li","year":"2016","unstructured":"Li Y, Shi H, Wang WM, Peng A, Jiang GR, Zhang JY, Ni ZH, He LQ, Niu JY, Wang NS, Mei CL, Xu XD, Guo ZY, Yuan WJ, Yan HD, Deng YY, Yu C, Cen J, Zhang Y, Chen N (2016) Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study. Medicine 95(24):e3872. https:\/\/doi.org\/10.1097\/md.0000000000003872","journal-title":"Medicine"},{"issue":"1","key":"4146_CR3","doi-asserted-by":"publisher","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","volume":"9","author":"ME Stauffer","year":"2014","unstructured":"Stauffer ME, Fan T (2014) Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE 9(1):e84943. https:\/\/doi.org\/10.1371\/journal.pone.0084943","journal-title":"PLoS ONE"},{"issue":"5","key":"4146_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/ckj\/sfaa054","volume":"13","author":"M Evans","year":"2020","unstructured":"Evans M, Bower H, Cockburn E, Jacobson SH, Barany P, Carrero JJ (2020) Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. Clin Kidney J 13(5):821\u2013827. https:\/\/doi.org\/10.1093\/ckj\/sfaa054","journal-title":"Clin Kidney J"},{"issue":"1","key":"4146_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12882-020-01746-4","volume":"21","author":"H van Haalen","year":"2020","unstructured":"van Haalen H, Jackson J, Spinowitz B, Milligan G, Moon R (2020) Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrol 21(1):88. https:\/\/doi.org\/10.1186\/s12882-020-01746-4","journal-title":"BMC Nephrol"},{"issue":"5","key":"4146_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1053\/j.jrn.2019.11.003","volume":"30","author":"J Hoshino","year":"2020","unstructured":"Hoshino J, Muenz D, Zee J, Sukul N, Speyer E, Guedes M, Lopes AA, Asahi K, van Haalen H, James G, Dhalwani N, Pecoits-Filho R, Bieber B, Robinson BM, Pisoni RL (2020) Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with stage 3\u20135 nondialysis CKD. J Ren Nutr 30(5):404\u2013414. https:\/\/doi.org\/10.1053\/j.jrn.2019.11.003","journal-title":"J Ren Nutr"},{"issue":"2","key":"4146_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1440-1797.2008.01065.x","volume":"14","author":"ML Thorp","year":"2009","unstructured":"Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH (2009) Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology 14(2):240\u2013246. https:\/\/doi.org\/10.1111\/j.1440-1797.2008.01065.x","journal-title":"Nephrology"},{"issue":"10","key":"4146_CR8","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10157-019-01767-w","volume":"23","author":"K Yahata","year":"2019","unstructured":"Yahata K, Seta K, Kikuchi Y, Koizumi M, Murata M, Wada H, Murakami S, Ohishi M, Tsuji H (2019) Treatment for renal anemia and outcomes in non-dialysis patients with chronic kidney disease: the current status of regional medicine according to the Kyoto Fushimi Renal Anemia (KFRA) study. Clin Exp Nephrol 23(10):1211\u20131220. https:\/\/doi.org\/10.1007\/s10157-019-01767-w","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"4146_CR9","doi-asserted-by":"publisher","first-page":"e0266243","DOI":"10.1371\/journal.pone.0266243","volume":"17","author":"B Abdelazeem","year":"2022","unstructured":"Abdelazeem B, Shehata J, Abbas KS, El-Shahat NA, Malik B, Savarapu P, Eltobgy M, Kunadi A (2022) The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials. PLoS ONE 17(4):e0266243. https:\/\/doi.org\/10.1371\/journal.pone.0266243","journal-title":"PLoS ONE"},{"issue":"16","key":"4146_CR10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s40265-022-01783-3","volume":"82","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, Minutolo R, De Nicola L, Del Vecchio L (2022) Evolving strategies in the treatment of anaemia in chronic kidney disease: the HIF-prolyl hydroxylase inhibitors. Drugs 82(16):1565\u20131589. https:\/\/doi.org\/10.1007\/s40265-022-01783-3","journal-title":"Drugs"},{"issue":"2","key":"4146_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.kint.2018.08.043","volume":"95","author":"F Imeri","year":"2019","unstructured":"Imeri F, Nolan KA, Bapst AM, Santambrogio S, Abreu-Rodr\u00edguez I, Spielmann P, Pfundstein S, Libertini S, Crowther L, Orlando IMC, Dahl SL, Keodara A, Kuo W, Kurtcuoglu V, Scholz CC, Qi W, Hummler E, Hoogewijs D, Wenger RH (2019) Generation of renal Epo-producing cell lines by conditional gene tagging reveals rapid HIF-2 driven Epo kinetics, cell autonomous feedback regulation, and a telocyte phenotype. Kidney Int 95(2):375\u2013387. https:\/\/doi.org\/10.1016\/j.kint.2018.08.043","journal-title":"Kidney Int"},{"issue":"10","key":"4146_CR12","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1093\/ndt\/gfm316","volume":"22","author":"F Artunc","year":"2007","unstructured":"Artunc F, Risler T (2007) Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease. Nephrol Dial Transplant 22(10):2900\u20132908. https:\/\/doi.org\/10.1093\/ndt\/gfm316","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"4146_CR13","doi-asserted-by":"publisher","first-page":"e13768","DOI":"10.1111\/apha.13768","volume":"234","author":"SL Dahl","year":"2022","unstructured":"Dahl SL, Pfundstein S, Hunkeler R, Dong X, Kn\u00f6pfel T, Spielmann P, Scholz CC, Nolan KA, Wenger RH (2022) Fate-mapping of erythropoietin-producing cells in mouse models of hypoxaemia and renal tissue remodelling reveals repeated recruitment and persistent functionality. Acta Physiol 234(3):e13768. https:\/\/doi.org\/10.1111\/apha.13768","journal-title":"Acta Physiol"},{"issue":"Pt 6","key":"4146_CR14","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1113\/jphysiol.2010.195057","volume":"589","author":"W Jelkmann","year":"2011","unstructured":"Jelkmann W (2011) Regulation of erythropoietin production. J Physiol 589(Pt 6):1251\u20131258. https:\/\/doi.org\/10.1113\/jphysiol.2010.195057","journal-title":"J Physiol"},{"issue":"4","key":"4146_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semnephrol.2006.06.001","volume":"26","author":"M Nangaku","year":"2006","unstructured":"Nangaku M, Eckardt K-U (2006) Pathogenesis of renal anemia. Semin Nephrol 26(4):261\u2013268","journal-title":"Semin Nephrol"},{"issue":"4","key":"4146_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/mnh.0000000000000420","volume":"27","author":"KA Nolan","year":"2018","unstructured":"Nolan KA, Wenger RH (2018) Source and microenvironmental regulation of erythropoietin in the kidney. Curr Opin Nephrol Hypertens 27(4):277\u2013282. https:\/\/doi.org\/10.1097\/mnh.0000000000000420","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"6","key":"4146_CR17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","volume":"69","author":"N Gupta","year":"2017","unstructured":"Gupta N, Wish JB (2017) Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis 69(6):815\u2013826. https:\/\/doi.org\/10.1053\/j.ajkd.2016.12.011","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"4146_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/cells8030207","volume":"8","author":"S Shu","year":"2019","unstructured":"Shu S, Wang Y, Zheng M, Liu Z, Cai J, Tang C, Dong Z (2019) Hypoxia and hypoxia-inducible factors in kidney injury and repair. Cells 8(3):207. https:\/\/doi.org\/10.3390\/cells8030207","journal-title":"Cells"},{"issue":"1","key":"4146_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/j.ajkd.2015.06.030","volume":"67","author":"M Bonomini","year":"2016","unstructured":"Bonomini M, Del Vecchio L, Sirolli V, Locatelli F (2016) New treatment approaches for the anemia of CKD. Am J Kidney Dis 67(1):133\u2013142. https:\/\/doi.org\/10.1053\/j.ajkd.2015.06.030","journal-title":"Am J Kidney Dis"},{"key":"4146_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3389\/fgene.2019.01134","volume":"10","author":"K Sato","year":"2019","unstructured":"Sato K, Kumagai N, Suzuki N (2019) Alteration of the DNA methylation signature of renal erythropoietin-producing cells governs the sensitivity to drugs targeting the hypoxia-response pathway in kidney disease progression. Front Genet 10:1134. https:\/\/doi.org\/10.3389\/fgene.2019.01134","journal-title":"Front Genet"},{"issue":"1","key":"4146_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00424-015-1740-2","volume":"468","author":"N Suzuki","year":"2016","unstructured":"Suzuki N, Yamamoto M (2016) Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis. Pflugers Arch 468(1):3\u201312. https:\/\/doi.org\/10.1007\/s00424-015-1740-2","journal-title":"Pflugers Arch"},{"issue":"2","key":"4146_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.kint.2022.04.026","volume":"102","author":"K Kaneko","year":"2022","unstructured":"Kaneko K, Sato Y, Uchino E, Toriu N, Shigeta M, Kiyonari H, Endo S, Fukuma S, Yanagita M (2022) Lineage tracing analysis defines erythropoietin-producing cells as a distinct subpopulation of resident fibroblasts with unique behaviors. Kidney Int 102(2):280\u2013292. https:\/\/doi.org\/10.1016\/j.kint.2022.04.026","journal-title":"Kidney Int"},{"issue":"10","key":"4146_CR23","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1681\/asn.2013010030","volume":"24","author":"T Souma","year":"2013","unstructured":"Souma T, Yamazaki S, Moriguchi T, Suzuki N, Hirano I, Pan X, Minegishi N, Abe M, Kiyomoto H, Ito S, Yamamoto M (2013) Plasticity of renal erythropoietin-producing cells governs fibrosis. J Am Soc Nephrol 24(10):1599\u20131616. https:\/\/doi.org\/10.1681\/asn.2013010030","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4146_CR24","doi-asserted-by":"publisher","first-page":"11254","DOI":"10.1038\/s41598-019-47766-5","volume":"9","author":"K Sato","year":"2019","unstructured":"Sato K, Hirano I, Sekine H, Miyauchi K, Nakai T, Kato K, Ito S, Yamamoto M, Suzuki N (2019) An immortalized cell line derived from renal erythropoietin-producing (REP) cells demonstrates their potential to transform into myofibroblasts. Sci Rep 9(1):11254. https:\/\/doi.org\/10.1038\/s41598-019-47766-5","journal-title":"Sci Rep"},{"issue":"8","key":"4146_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00424-022-02714-7","volume":"474","author":"SL Dahl","year":"2022","unstructured":"Dahl SL, Bapst AM, Khodo SN, Scholz CC, Wenger RH (2022) Fount, fate, features, and function of renal erythropoietin-producing cells. Pflugers Arch 474(8):783\u2013797. https:\/\/doi.org\/10.1007\/s00424-022-02714-7","journal-title":"Pflugers Arch"},{"key":"4146_CR26","doi-asserted-by":"publisher","first-page":"690496","DOI":"10.3389\/fphys.2021.690496","volume":"12","author":"Y Xu","year":"2021","unstructured":"Xu Y, Kong X, Li J, Cui T, Wei Y, Xu J, Zhu Y, Zhu X (2021) Mild hypoxia enhances the expression of HIF and VEGF and triggers the response to injury in rat kidneys. Front Physiol 12:690496. https:\/\/doi.org\/10.3389\/fphys.2021.690496","journal-title":"Front Physiol"},{"issue":"1","key":"4146_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jemt.1070250106","volume":"25","author":"ST Koury","year":"1993","unstructured":"Koury ST, Bondurant MC, Semenza GL, Koury MJ (1993) The use of in situ hybridization to study erythropoietin gene expression in murine kidney and liver. Microsc Res Tech 25(1):29\u201339. https:\/\/doi.org\/10.1002\/jemt.1070250106","journal-title":"Microsc Res Tech"},{"issue":"12","key":"4146_CR28","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1681\/asn.2010010116","volume":"21","author":"WM Bernhardt","year":"2010","unstructured":"Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, G\u00fcnzler V, Eckardt KU (2010) Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21(12):2151\u20132156. https:\/\/doi.org\/10.1681\/asn.2010010116","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"4146_CR29","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1159\/000502525","volume":"44","author":"JH Li","year":"2019","unstructured":"Li JH, Luo JF, Jiang Y, Ma YJ, Ji YQ, Zhu GL, Zhou C, Chu HW, Zhang HD (2019) Red blood cell lifespan shortening in patients with early-stage chronic kidney disease. Kidney Blood Press Res 44(5):1158\u20131165. https:\/\/doi.org\/10.1159\/000502525","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"4146_CR30","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1523-1755.2004.00880.x","volume":"66","author":"T Fehr","year":"2004","unstructured":"Fehr T, Ammann P, Garzoni D, Korte W, Fierz W, Rickli H, W\u00fcthrich RP (2004) Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int 66(3):1206\u20131211. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00880.x","journal-title":"Kidney Int"},{"issue":"3","key":"4146_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/1744-9987.12685","volume":"22","author":"M Tanaka","year":"2018","unstructured":"Tanaka M, Komaba H, Fukagawa M (2018) Emerging association between parathyroid hormone and anemia in hemodialysis patients. Ther Apher Dial 22(3):242\u2013245. https:\/\/doi.org\/10.1111\/1744-9987.12685","journal-title":"Ther Apher Dial"},{"key":"4146_CR32","doi-asserted-by":"publisher","first-page":"100102","DOI":"10.1016\/j.crphar.2022.100102","volume":"3","author":"AA Joharapurkar","year":"2022","unstructured":"Joharapurkar AA, Patel VJ, Kshirsagar SG, Patel MS, Savsani HH, Kajavadara C, Valani D, Jain MR (2022) Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state. Curr Res Pharmacol Drug Discov 3:100102. https:\/\/doi.org\/10.1016\/j.crphar.2022.100102","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"9","key":"4146_CR33","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10157-022-02227-8","volume":"26","author":"S Tanaka","year":"2022","unstructured":"Tanaka S, Kitamura H, Tsuruya K, Kitazono T, Nakano T (2022) Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study. Clin Exp Nephrol 26(9):867\u2013879. https:\/\/doi.org\/10.1007\/s10157-022-02227-8","journal-title":"Clin Exp Nephrol"},{"key":"4146_CR34","doi-asserted-by":"publisher","first-page":"110583","DOI":"10.1016\/j.cellsig.2022.110583","volume":"104","author":"E Hamza","year":"2023","unstructured":"Hamza E, Vallejo-Mudarra M, Ouled-Haddou H, Garc\u00eda-Caballero C, Guerrero-Hue M, Santier L, Rayego-Mateos S, Larabi IA, Alvarez JC, Gar\u00e7on L, Massy ZA, Choukroun G, Moreno JA, Metzinger L, Meuth VM (2023) Indoxyl sulfate impairs erythropoiesis at BFU-E stage in chronic kidney disease. Cell Signal 104:110583. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110583","journal-title":"Cell Signal"},{"issue":"15","key":"4146_CR35","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1177\/15353702221097320","volume":"247","author":"T Duangchan","year":"2022","unstructured":"Duangchan T, Rattanasompattikul M, Chitchongyingcharoen N, Mas-Oodi S, Promkan M, Rongkiettechakorn N, Korpraphong S, Supokawej A (2022) Indoxyl sulfate impairs in vitro erythropoiesis by triggering apoptosis and senescence. Exp Biol Med 247(15):1350\u20131363. https:\/\/doi.org\/10.1177\/15353702221097320","journal-title":"Exp Biol Med"},{"issue":"11","key":"4146_CR36","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3390\/healthcare9111452","volume":"9","author":"CC Hsieh","year":"2021","unstructured":"Hsieh CC, Chan MJ, Su YJ, Fu JF, Wang IK, Chen CY, Weng CH, Huang WH, Hsu CW, Yen TH (2021) Bone marrow hypocellularity in patients with end-stage kidney disease. Healthcare 9(11):1452. https:\/\/doi.org\/10.3390\/healthcare9111452","journal-title":"Healthcare"},{"issue":"4","key":"4146_CR37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.33594\/000000396","volume":"55","author":"GF Dias","year":"2021","unstructured":"Dias GF, Tozoni SS, Bohnen G, Grobe N, Rodrigues SD, Meireles T, Nakao LS, Pecoits-Filho R, Kotanko P, Moreno-Amaral AN (2021) Uremia and inadequate oxygen supply induce eryptosis and intracellular hypoxia in red blood cells. Cell Physiol Biochem 55(4):449\u2013459. https:\/\/doi.org\/10.33594\/000000396","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"4146_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/iub.2192","volume":"72","author":"L Guti\u00e9rrez","year":"2020","unstructured":"Guti\u00e9rrez L, Caballero N, Fern\u00e1ndez-Calleja L, Karkoulia E, Strouboulis J (2020) Regulation of GATA1 levels in erythropoiesis. IUBMB Life 72(1):89\u2013105. https:\/\/doi.org\/10.1002\/iub.2192","journal-title":"IUBMB Life"},{"issue":"10","key":"4146_CR39","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1093\/nar\/gkad167","volume":"51","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang P, Zhang J, Gong H, Zhang X, Song J, Nie L, Peng Y, Li Y, Peng H, Cui Y, Li H, Hu B, Mi J, Liang L, Liu H, Zhang J, Ye M, Yazdanbakhsh K, Mohandas N, An X, Han X, Liu J (2023) The novel GATA1-interacting protein HES6 is an essential transcriptional cofactor for human erythropoiesis. Nucleic Acids Res 51(10):4774\u20134790. https:\/\/doi.org\/10.1093\/nar\/gkad167","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"4146_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nm.3814","volume":"21","author":"VG Sankaran","year":"2015","unstructured":"Sankaran VG, Weiss MJ (2015) Anemia: progress in molecular mechanisms and therapies. Nat Med 21(3):221\u2013230. https:\/\/doi.org\/10.1038\/nm.3814","journal-title":"Nat Med"},{"issue":"11","key":"4146_CR41","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.3390\/nu13113732","volume":"13","author":"L Lukas","year":"2021","unstructured":"Lukas L, Dietmar F, Katharina K, G\u00fcnter W (2021) Physiology and inflammation driven pathophysiology of iron homeostasis\u2014mechanistic insights into anemia of inflammation and its treatment. Nutrients 13(11):3732\u20133732","journal-title":"Nutrients"},{"issue":"5","key":"4146_CR42","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.4314\/tjpr.v15i5.26","volume":"15","author":"X Xuekun","year":"2016","unstructured":"Xuekun X, Wenbo Z, Huishan S (2016) Role of erythropoietin in renal anemia therapy. Tropic J Pharmaceut Res 15(5):1083\u20131088","journal-title":"Tropic J Pharmaceut Res"},{"issue":"1","key":"4146_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000496492","volume":"142","author":"A Gafter-Gvili","year":"2019","unstructured":"Gafter-Gvili A, Schechter A, Rozen-Zvi B (2019) Iron deficiency anemia in chronic kidney disease. Acta Haematol 142(1):44\u201350. https:\/\/doi.org\/10.1159\/000496492","journal-title":"Acta Haematol"},{"issue":"6","key":"4146_CR44","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1053\/j.ajkd.2021.09.017","volume":"79","author":"JW Bazeley","year":"2022","unstructured":"Bazeley JW, Wish JB (2022) Recent and emerging therapies for iron deficiency in anemia of CKD: a review. Am J Kidney Dis 79(6):868\u2013876. https:\/\/doi.org\/10.1053\/j.ajkd.2021.09.017","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"4146_CR45","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.ekir.2021.05.020","volume":"6","author":"OM Guti\u00e9rrez","year":"2021","unstructured":"Guti\u00e9rrez OM (2021) Treatment of iron deficiency anemia in CKD and end-stage kidney disease. Kidney Int Rep 6(9):2261\u20132269. https:\/\/doi.org\/10.1016\/j.ekir.2021.05.020","journal-title":"Kidney Int Rep"},{"issue":"5","key":"4146_CR46","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/14728222.2019.1599358","volume":"23","author":"J Malyszko","year":"2019","unstructured":"Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J (2019) Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Targets 23(5):407\u2013421. https:\/\/doi.org\/10.1080\/14728222.2019.1599358","journal-title":"Expert Opin Ther Targets"},{"key":"4146_CR47","doi-asserted-by":"publisher","first-page":"642296","DOI":"10.3389\/fmed.2021.642296","volume":"8","author":"J Portol\u00e9s","year":"2021","unstructured":"Portol\u00e9s J, Mart\u00edn L, Broseta JJ, Cases A (2021) Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med 8:642296. https:\/\/doi.org\/10.3389\/fmed.2021.642296","journal-title":"Front Med"},{"issue":"1","key":"4146_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000527835","volume":"9","author":"J Li","year":"2023","unstructured":"Li J, Haase VH, Hao CM (2023) Updates on hypoxia-inducible factor prolyl hydroxylase inhibitors in the treatment of renal anemia. Kidney Dis 9(1):1\u201311. https:\/\/doi.org\/10.1159\/000527835","journal-title":"Kidney Dis"},{"issue":"6","key":"4146_CR49","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1159\/000533304","volume":"9","author":"X Wang","year":"2023","unstructured":"Wang X, Wei C, Zhao D, Sun X, Zhu F, Mei Y, Ma Q, Cai G, Chen X, Li P (2023) Iron supplements concomitant within hypoxia-inducible factor prolyl hydroxylase domain inhibitors in the treatment of chronic kidney disease anemia. Kidney Dis 9(6):485\u2013497. https:\/\/doi.org\/10.1159\/000533304","journal-title":"Kidney Dis"},{"issue":"9","key":"4146_CR50","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3390\/cells9092039","volume":"9","author":"E Hamza","year":"2020","unstructured":"Hamza E, Metzinger L, Metzinger-Le Meuth V (2020) Uremic toxins affect erythropoiesis during the course of chronic kidney disease: a review. Cells 9(9):2039. https:\/\/doi.org\/10.3390\/cells9092039","journal-title":"Cells"},{"issue":"12","key":"4146_CR51","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/toxins13120909","volume":"13","author":"T Nakano","year":"2021","unstructured":"Nakano T, Watanabe H, Imafuku T, Tokumaru K, Fujita I, Arimura N, Maeda H, Tanaka M, Matsushita K, Fukagawa M, Maruyama T (2021) Indoxyl sulfate contributes to mTORC1-induced renal fibrosis via the OAT\/NADPH oxidase\/ROS pathway. Toxins 13(12):909. https:\/\/doi.org\/10.3390\/toxins13120909","journal-title":"Toxins"},{"issue":"3","key":"4146_CR52","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3390\/ijms21030725","volume":"21","author":"A Gluba-Brz\u00f3zka","year":"2020","unstructured":"Gluba-Brz\u00f3zka A, Franczyk B, Olszewski R, Rysz J (2020) The influence of inflammation on anemia in CKD patients. Int J Mol Sci 21(3):725. https:\/\/doi.org\/10.3390\/ijms21030725","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4146_CR53","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/moh.0000000000000236","volume":"23","author":"CY Wang","year":"2016","unstructured":"Wang CY, Babitt JL (2016) Hepcidin regulation in the anemia of inflammation. Curr Opin Hematol 23(3):189\u2013197. https:\/\/doi.org\/10.1097\/moh.0000000000000236","journal-title":"Curr Opin Hematol"},{"issue":"12","key":"4146_CR54","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1056\/NEJMra1804281","volume":"381","author":"T Ganz","year":"2019","unstructured":"Ganz T (2019) Anemia of inflammation. N Engl J Med 381(12):1148\u20131157. https:\/\/doi.org\/10.1056\/NEJMra1804281","journal-title":"N Engl J Med"},{"key":"4146_CR55","doi-asserted-by":"publisher","first-page":"951937","DOI":"10.3389\/fimmu.2022.951937","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Erlacher M, Fernandez-Orth J (2022) The role of inflammation in hematopoiesis and bone marrow failure: what can we learn from mouse models? Front Immunol 13:951937. https:\/\/doi.org\/10.3389\/fimmu.2022.951937","journal-title":"Front Immunol"},{"issue":"3","key":"4146_CR56","doi-asserted-by":"publisher","first-page":"8183","DOI":"10.4081\/hr.2019.8183","volume":"11","author":"K Amnuay","year":"2019","unstructured":"Amnuay K, Srisawat N, Wudhikarn K, Assanasen T, Polprasert C (2019) Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients. Hematol Rep 11(3):8183. https:\/\/doi.org\/10.4081\/hr.2019.8183","journal-title":"Hematol Rep"},{"issue":"24","key":"4146_CR57","doi-asserted-by":"publisher","first-page":"7373","DOI":"10.3390\/jcm11247373","volume":"11","author":"S Rao","year":"2022","unstructured":"Rao S, Zhang J, Lin J, Wan J, Chen Y (2022) Association of red blood cell life span with abnormal changes in cardiac structure and function in non-dialysis patients with chronic kidney disease stages 3\u20135. J Clin Med 11(24):7373. https:\/\/doi.org\/10.3390\/jcm11247373","journal-title":"J Clin Med"},{"issue":"10","key":"4146_CR58","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1182\/blood-2008-07-161166","volume":"112","author":"N Mohandas","year":"2008","unstructured":"Mohandas N, Gallagher PG (2008) Red cell membrane: past, present, and future. Blood 112(10):3939\u20133948. https:\/\/doi.org\/10.1182\/blood-2008-07-161166","journal-title":"Blood"},{"issue":"9","key":"4146_CR59","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1002\/jcp.30322","volume":"236","author":"A Remigante","year":"2021","unstructured":"Remigante A, Morabito R, Marino A (2021) Band 3 protein function and oxidative stress in erythrocytes. J Cell Physiol 236(9):6225\u20136234. https:\/\/doi.org\/10.1002\/jcp.30322","journal-title":"J Cell Physiol"},{"issue":"6","key":"4146_CR60","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1159\/000522133","volume":"47","author":"D Li","year":"2022","unstructured":"Li D, Zheng X, Zhang Y, Li X, Chen X, Yin Y, Hu J, Li J, Guo M, Wang X (2022) What should be responsible for eryptosis in chronic kidney disease? Kidney Blood Press Res 47(6):375\u2013390. https:\/\/doi.org\/10.1159\/000522133","journal-title":"Kidney Blood Press Res"},{"issue":"23","key":"4146_CR61","doi-asserted-by":"publisher","first-page":"7167","DOI":"10.3390\/jcm11237167","volume":"11","author":"A Clementi","year":"2022","unstructured":"Clementi A, Virz\u00ec GM, Milan Manani S, Battaglia GG, Ronco C, Zanella M (2022) Eryptosis in patients with chronic kidney disease: a possible relationship with oxidative stress and inflammatory markers. J Clin Med 11(23):7167. https:\/\/doi.org\/10.3390\/jcm11237167","journal-title":"J Clin Med"},{"key":"4146_CR62","doi-asserted-by":"publisher","first-page":"598148","DOI":"10.3389\/fcell.2020.598148","volume":"8","author":"GF Dias","year":"2020","unstructured":"Dias GF, Grobe N, Rogg S, J\u00f6rg DJ, Pecoits-Filho R, Moreno-Amaral AN, Kotanko P (2020) The role of eryptosis in the pathogenesis of renal anemia: insights from basic research and mathematical modeling. Front Cell Dev Biol 8:598148. https:\/\/doi.org\/10.3389\/fcell.2020.598148","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"4146_CR63","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1159\/000484215","volume":"42","author":"F Lang","year":"2017","unstructured":"Lang F, Bissinger R, Abed M, Artunc F (2017) Eryptosis\u2014the neglected cause of anemia in end stage renal disease. Kidney Blood Press Res 42(4):749\u2013760. https:\/\/doi.org\/10.1159\/000484215","journal-title":"Kidney Blood Press Res"},{"key":"4146_CR64","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3389\/fcell.2020.00597","volume":"8","author":"M F\u00f6ller","year":"2020","unstructured":"F\u00f6ller M, Lang F (2020) Ion transport in eryptosis, the suicidal death of erythrocytes. Front Cell Dev Biol 8:597. https:\/\/doi.org\/10.3389\/fcell.2020.00597","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"4146_CR65","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/mnh.0000000000000957","volume":"33","author":"R Bissinger","year":"2024","unstructured":"Bissinger R, Qadri SM, Artunc F (2024) Eryptosis: a driver of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens 33(2):220\u2013225. https:\/\/doi.org\/10.1097\/mnh.0000000000000957","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"4146_CR66","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/febs.14606","volume":"286","author":"R Bissinger","year":"2019","unstructured":"Bissinger R, Bhuyan AAM, Qadri SM, Lang F (2019) Oxidative stress, eryptosis and anemia: a pivotal mechanistic nexus in systemic diseases. Febs j 286(5):826\u2013854. https:\/\/doi.org\/10.1111\/febs.14606","journal-title":"Febs j"},{"issue":"18","key":"4146_CR67","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.3390\/jcm11185329","volume":"11","author":"GM Virz\u00ec","year":"2022","unstructured":"Virz\u00ec GM, Mattiotti M, Clementi A, Milan Manani S, Battaglia GG, Ronco C, Zanella M (2022) In vitro induction of eryptosis by uremic toxins and inflammation mediators in healthy red blood cells. J Clin Med 11(18):5329. https:\/\/doi.org\/10.3390\/jcm11185329","journal-title":"J Clin Med"},{"issue":"6","key":"4146_CR68","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.3390\/ijms24065079","volume":"24","author":"SA Alghareeb","year":"2023","unstructured":"Alghareeb SA, Alfhili MA, Fatima S (2023) Molecular mechanisms and pathophysiological significance of eryptosis. Int J Mol Sci 24(6):5079. https:\/\/doi.org\/10.3390\/ijms24065079","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4146_CR69","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/sdi.13037","volume":"35","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Li JH, Luo JF, Han QS, Zhu SL, Ma YJ, Zhang HD (2022) Hemodiafiltration improves red blood cell lifespan in patients with end-stage renal disease. Semin Dial 35(3):215\u2013221. https:\/\/doi.org\/10.1111\/sdi.13037","journal-title":"Semin Dial"},{"key":"4146_CR70","doi-asserted-by":"publisher","first-page":"794","DOI":"10.33594\/000000173","volume":"53","author":"SS Tozoni","year":"2019","unstructured":"Tozoni SS, Dias GF, Bohnen G, Grobe N, Pecoits-Filho R, Kotanko P, Moreno-Amaral AN (2019) Uremia and hypoxia independently induce eryptosis and erythrocyte redox imbalance. Cell Physiol Biochem 53:794\u2013804. https:\/\/doi.org\/10.33594\/000000173","journal-title":"Cell Physiol Biochem"},{"issue":"7","key":"4146_CR71","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/toxins10070280","volume":"10","author":"GF Dias","year":"2018","unstructured":"Dias GF, Bonan NB, Steiner TM, Tozoni SS, Rodrigues S, Nakao LS, Kuntsevich V, Pecoits Filho R, Kotanko P, Moreno-Amaral AN (2018) Indoxyl sulfate, a uremic toxin, stimulates reactive oxygen species production and erythrocyte cell death supposedly by an organic anion transporter 2 (OAT2) and NADPH oxidase activity-dependent pathways. Toxins 10(7):280. https:\/\/doi.org\/10.3390\/toxins10070280","journal-title":"Toxins"},{"issue":"1","key":"4146_CR72","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.tracli.2017.08.001","volume":"25","author":"M Bardyn","year":"2018","unstructured":"Bardyn M, Tissot JD, Prudent M (2018) Oxidative stress and antioxidant defenses during blood processing and storage of erythrocyte concentrates. Transfus Clin Biol 25(1):96\u2013100. https:\/\/doi.org\/10.1016\/j.tracli.2017.08.001","journal-title":"Transfus Clin Biol"},{"issue":"10","key":"4146_CR73","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3390\/antiox9100929","volume":"9","author":"J Sudnitsyna","year":"2020","unstructured":"Sudnitsyna J, Skverchinskaya E, Dobrylko I, Nikitina E, Gambaryan S, Mindukshev I (2020) Microvesicle formation induced by oxidative stress in human erythrocytes. Antioxidants 9(10):929. https:\/\/doi.org\/10.3390\/antiox9100929","journal-title":"Antioxidants"},{"issue":"5","key":"4146_CR74","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1053\/j.ajkd.2019.04.022","volume":"74","author":"S Thavarajah","year":"2019","unstructured":"Thavarajah S, Choi MJ (2019) The use of erythropoiesis-stimulating agents in patients with CKD and cancer: a clinical approach. Am J Kidney Dis 74(5):667\u2013674. https:\/\/doi.org\/10.1053\/j.ajkd.2019.04.022","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"4146_CR75","first-page":"3434","volume":"125","author":"QG Zhou","year":"2012","unstructured":"Zhou QG, Jiang JP, Wu SJ, Tian JW, Chen JH, Yu XQ, Chen PY, Mei CL, Xiong F, Shi W, Zhou W, Liu XS, Sun SR, Xie D, Liu J, Xu X, Hou FF (2012) Current pattern of Chinese dialysis units: a cohort study in a representative sample of units. Chin Med J 125(19):3434\u20133439","journal-title":"Chin Med J"},{"issue":"5","key":"4146_CR76","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","volume":"380","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, Ford I (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380(5):447\u2013458. https:\/\/doi.org\/10.1056\/NEJMoa1810742","journal-title":"N Engl J Med"},{"issue":"6","key":"4146_CR77","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1681\/asn.2018101007","volume":"30","author":"Y Sakaguchi","year":"2019","unstructured":"Sakaguchi Y, Hamano T, Wada A, Masakane I (2019) Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol 30(6):1037\u20131048. https:\/\/doi.org\/10.1681\/asn.2018101007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"4146_CR78","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.xkme.2020.06.008","volume":"2","author":"B Cizman","year":"2020","unstructured":"Cizman B, Smith HT, Camejo RR, Casillas L, Dhillon H, Mu F, Wu E, Xie J, Zuckerman P, Coyne D (2020) Clinical and economic outcomes of erythropoiesis-stimulating agent hyporesponsiveness in the post-bundling era. Kidney Med 2(5):589-599.e581. https:\/\/doi.org\/10.1016\/j.xkme.2020.06.008","journal-title":"Kidney Med"},{"issue":"3","key":"4146_CR79","doi-asserted-by":"publisher","first-page":"sfae051","DOI":"10.1093\/ckj\/sfae051","volume":"17","author":"T Nakanishi","year":"2024","unstructured":"Nakanishi T, Kuragano T (2024) Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia. Clin Kidney J 17(3):sfae051. https:\/\/doi.org\/10.1093\/ckj\/sfae051","journal-title":"Clin Kidney J"},{"key":"4146_CR80","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2501-23","author":"E Imai","year":"2023","unstructured":"Imai E, Imai A (2023) The comparison between vadadustat and daprodustat regarding dose, cost, and safety of treatment for renal anemia in non-dialysis patients with chronic kidney diseases. Intern Med. https:\/\/doi.org\/10.2169\/internalmedicine.2501-23","journal-title":"Intern Med"},{"issue":"10","key":"4146_CR81","doi-asserted-by":"publisher","first-page":"e47430","DOI":"10.7759\/cureus.47430","volume":"15","author":"N Damarlapally","year":"2023","unstructured":"Damarlapally N, Thimmappa V, Irfan H, Sikandari M, Madhu K, Desai A, Pavani P, Zakir S, Gupta M, Khosa MM, Kotak S, Varrassi G, Khatri M, Kumar S (2023) Safety and efficacy of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoietin-stimulating agents in treating anemia in renal patients (with or without dialysis): a meta-analysis and systematic review. Cureus 15(10):e47430. https:\/\/doi.org\/10.7759\/cureus.47430","journal-title":"Cureus"},{"issue":"1","key":"4146_CR82","doi-asserted-by":"publisher","first-page":"sfad143","DOI":"10.1093\/ckj\/sfad143","volume":"17","author":"R Minutolo","year":"2024","unstructured":"Minutolo R, Liberti ME, Simeon V, Sasso FC, Borrelli S, De Nicola L, Garofalo C (2024) Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials. Clin Kidney J 17(1):sfad143. https:\/\/doi.org\/10.1093\/ckj\/sfad143","journal-title":"Clin Kidney J"},{"issue":"10","key":"4146_CR83","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.3390\/nu11102424","volume":"11","author":"S Begum","year":"2019","unstructured":"Begum S, Latunde-Dada GO (2019) Anemia of inflammation with an emphasis on chronic kidney disease. Nutrients 11(10):2424. https:\/\/doi.org\/10.3390\/nu11102424","journal-title":"Nutrients"},{"issue":"5","key":"4146_CR84","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/bcp.13877","volume":"85","author":"M Sheetz","year":"2019","unstructured":"Sheetz M, Barrington P, Callies S, Berg PH, McColm J, Marbury T, Decker B, Dyas GL, Truhlar SME, Benschop R, Leung D, Berg J, Witcher DR (2019) Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol 85(5):935\u2013948. https:\/\/doi.org\/10.1111\/bcp.13877","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4146_CR85","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/cells11030503","volume":"11","author":"P Dreischer","year":"2022","unstructured":"Dreischer P, Duszenko M, Stein J, Wieder T (2022) Eryptosis: programmed death of nucleus-free, iron-filled blood cells. Cells 11(3):503. https:\/\/doi.org\/10.3390\/cells11030503","journal-title":"Cells"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04146-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-04146-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04146-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T16:05:04Z","timestamp":1728489904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-04146-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":85,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["4146"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-04146-x","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}